Kamada (KMDA) Reports Q1 Loss of $0.11/Share; Reaffirms FY Rev. Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Kamada (KMDA) Reports Q1 Loss of $0.11/Share; Reaffirms FY Rev. Guidance

Kamada Reports 2017 First Quarter Financial Results

May 16, 2017 7:00 AM EDT

Reaffirms revenue guidance of $100 million for 2017

Proprietary Products segment for 2017 projected at $76-$78 million, up at least 36% compared to 2016

Conference call today at 8:30 am Eastern Time

NESS ZIONA, Israel, May 16, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd.  (Nasdaq: KMDA) (TASE:KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial results for the first quarter ended March 31, 2017. 

Our first quarter revenues were impacted by a delay in completing a periodic validation of our... More